Article
Oncology
Jeong A. Park, Nai-Kong Cheung
Summary: The study found that using multi-antigen targeting EATs can maintain target antigen specificity and anti-tumor potency, with substantially less cytokine release in the presence of tumor cells compared to mixing multiple BsAbs with unarmed T cells. Dual-armed EATs or multi-armed EATs effectively suppressed tumor growth and were highly efficient in preventing clonal escape.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Vita Golubovskaya, Hua Zhou, Feng Li, Robert Berahovich, Jinying Sun, Michael Valentine, Shirley Xu, Hizkia Harto, John Sienkiewicz, Yanwei Huang, Lijun Wu
Summary: This study focused on developing novel CS1 CAR-T cells and bispecific CS1-BCMA CAR-T cells for targeting multiple myeloma. The experimental results demonstrated that these cells effectively killed multiple myeloma cells, showing promise for future clinical trials.
Article
Chemistry, Multidisciplinary
Valeria Ukrainskaya, Yuri Rubtsov, Dmitry Pershin, Nadezhda Podoplelova, Stanislav Terekhov, Igor Yaroshevich, Anstasiia Sokolova, Dmitry Bagrov, Elena Kulakovskaya, Victoria Shipunova, Sergey Deyev, Rustam Ziganshin, Aleksandr Chernov, Georgii Telegin, Eugene Maksimov, Oleg Markov, Anastasiya Oshchepkova, Marina Zenkova, Jia Xie, Hongkai Zhang, Alexander Gabibov, Michael Maschan, Alexey Stepanov, Richard Lerner
Summary: The development of CAR-T therapy has achieved success in the treatment of B cell leukemia, but the expansion of CAR-T cells remains challenging with current protocols. A novel approach using cell-derived membrane vesicles has been proposed, showing greater potential in stimulating, proliferating, and enhancing the functional activity of CAR-T cells.
Article
Oncology
Tsung-Yi Lin, Jeong A. Park, Alan Long, Hong-Fen Guo, Nai-Kong Cheung
Summary: The study developed a T cell-engaging bispecific antibody named BC261, which demonstrated potent cytotoxicity against EFT, prostate cancer, and canine osteosarcoma cell lines and showed superior antitumor effects in vivo. BC261 not only promoted T cell infiltration into tumors but also exhibited significant antitumor efficacy against various cancer types.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Selma Bekri, Reunet Rodney-Sandy, Diana Gruenstein, Anna Mei, Bjarne Bogen, John Castle, Daniel Levey, Hearn Jay Cho
Summary: This study demonstrates that a vaccine targeting a tumor-specific neoantigen efficiently induces CD4 T cell-mediated tumor protection in a mouse model. The vaccine does not directly induce cytotoxic activity in CD4 T cells, but activation of CD8 CTL against tumor-associated antigens not present in the vaccine is a major mechanism of tumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Hanley N. Abramson
Summary: The landscape of therapeutic measures to treat multiple myeloma has changed significantly in recent years, primarily due to the introduction of new classes of small molecules and immunotherapeutic agents. These advancements have led to improved survival rates, but challenges such as drug resistance and relapse remain. This review discusses the currently available and emerging immunotherapeutic agents for multiple myeloma, highlighting their benefits and the challenges that need to be addressed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Karlijn de Joode, Sharon Veenbergen, Claudia Kransse, Dian Kortleve, Reno Debets, Ron H. J. Mathijssen, Arjen Joosse, Marco W. J. Schreurs, Astrid A. M. van der Veldt
Summary: A study showed that the presence of tumor-associated antibodies correlated with response to immune checkpoint inhibitor treatment in patients with metastatic melanoma. However, a new study failed to validate and extend these findings and did not identify other cancer germline antigens as predictive biomarkers of response to immune checkpoint inhibitors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Meera Mohan, Theresa Camille Maatman, Carolina Schinke
Summary: The introduction of monoclonal antibodies in the treatment of multiple myeloma has significantly improved patient outcomes, but the majority of patients will eventually relapse, highlighting the need for novel therapies like bispecific antibodies and chimeric antigen receptor T cells. These emerging treatments show promising results in heavily pretreated and refractory patients, and there is optimism that they may lead to sustained remission and a possible cure in the future.
Article
Oncology
Jeong A. Park, Madelyn Espinosa-Cotton, Hong-fen Guo, Sebastien Monette, Nai-Kong Cheung
Summary: This study demonstrates that using anti-VEGF antibodies can significantly improve the therapeutic efficacy of T cell immunotherapies by increasing HEVs and promoting the infiltration of cytotoxic CD8(+) TILs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Cirino Botta, Francesco Mendicino, Enrica Antonia Martino, Ernesto Vigna, Domenica Ronchetti, Pierpaolo Correale, Fortunato Morabito, Antonino Neri, Massimo Gentile
Summary: The article highlights the significance of immunotherapy for multiple myeloma and discusses the impact of main immune components on disease progression and response to cancer treatments. It also points out potential weaknesses in the tumor-promoting interactions and new therapeutic opportunities.
Review
Oncology
Jennifer Sun, Chaelee Park, Nicole Guenthner, Shannon Gurley, Luna Zhang, Berit Lubben, Ola Adebayo, Hannah Bash, Yixuan Chen, Mina Maksimos, Barbara Muz, Abdel Kareem Azab
Summary: MM is a cancer of plasma cells in the bone marrow, with the tumor microenvironment playing a critical role in disease progression. TAMs in the TME have been found to support tumor survival and chemoresistance, highlighting the importance of exploring macrophage-targeted immunotherapy in MM treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Fabiola De Luca, Alessandro Allegra, Carla Di Chio, Santo Previti, Maria Zappala, Roberta Ettari
Summary: Multiple myeloma is an incurable hematologic cancer characterized by immunological alterations in myeloid cells and lymphocytes. The current first-line therapy involves chemotherapy, but there is a high relapse rate and refractory MM cases. New monoclonal antibodies (Mab) including daratumumab, isatuximab, and elotuzumab, along with bispecific antibodies and CAR T cell therapy, have shown promise in immunotherapy for MM. CD38 (daratumumab and isatuximab), SLAM7 (elotuzumab) and BCMA (belantamab mafodotin) are the main antibody targets for MM treatment. Although MM is still incurable, combining the available drugs offers hope for improving outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Alana L. Keller, Daniel W. Sherbenou, Peter A. Forsberg, Tomer M. Mark
Summary: Multiple myeloma is an incurable hematologic malignancy characterized by initial treatment response followed by resistance development. Novel immunotherapeutics utilizing patients' own T cells, such as CAR T cell therapy and bispecific antibodies, have displayed impressive efficacy in clinical trials for myeloma patients.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Marcin Jasinski, Grzegorz W. Basak, Wieslaw W. Jedrzejczak
Summary: CAR-T cell therapy is a promising approach for the treatment of multiple myeloma, with receptors targeting BCMA showing positive results in clinical trials. However, limitations of this therapy include high relapse rates in most patients and potential serious adverse events. Further research is needed to enhance the effectiveness and safety of CAR-T cell therapy in treating multiple myeloma.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Sonia More, Laura Corvatta, Valentina Maria Manieri, Attilio Olivieri, Massimo Offidani
Summary: In newly diagnosed multiple myeloma patients, the introduction of three-drug and four-drug combinations has significantly improved response rates and overall survival. Long-term therapies are effective but expensive and may have toxic effects. Ongoing trials are evaluating the possibility of intensifying or de-intensifying treatment based on minimal residual disease status. New generation immunotherapies have shown promising results in relapsed/refractory patients. The management of multiple myeloma is still a difficult challenge, and risk stratification and personalized treatment strategies are being explored.